In the Spotlight
Read the article, “Entrectinib in NTRK-, ROS1-, or ALK-rearranged cancers,” by Alexander Drilon et al., reporting results of two phase 1 clinical trials, in Cancer Discovery.
Read “Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy” by Wang and colleagues in Cancer Research. Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. Wang, et al.’s findings suggest that the poor efficacy of anti-PD-1 as an immune checkpoint therapy for many patients could be accentuated greatly by adjuvant radiotherapy, thereby broadening its useful application against cancers, where robust but relatively infrequent responses have been documented. Read the Cancer Research February 15th issue.
Read the recently published article, "Aspirin Use and Reduced Risk of Pancreatic Cancer," Harvey A. Risch, et al, in Cancer Epidemiology, Biomarkers & Prevention.